Abstract
The hypotensive effect of hydralazine (1-hydrazinophthalazine, shown in Fig. 1 with related hydrazines) was first reported by Gross et al. (1950) and shortly afterwards it was shown that the compound was effective in lowering blood pressure in man and could be used in anti-hypertensive therapy (Schroeder, 1951; Page, 1951). The role of hydralazine in the treatment of hypertension increased with the use of beta-adrenergic antagonists, which reduce the major reflex effects of vasodilator-induced hypotension, namely tachycardia and an increase in the activity of the renin-angiotensin system (see Koch-Weser, 1976).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ablad, B. (1963). Acta. pharmacol. toxicol. (Kbh.), 20, Suppl. 1, 1–53.
Andersson, R. (1973). Acta pharmacol. toxicol., (Kbh.) 32, 321–336.
Bein, H.J., Gross, F., Tripod, J. and Meier, R. (1953). Schweiz. med. Wschr., 83, 336–340.
Brown, C.M. and Collis, M.G. (1981). European J. Pharmacol., 76, 275–277.
Brown, N.L., Chevillard, C. and Worcel, M. (1983). J. Pharmacol. Exp. Ther., 226, 512–518.
Brunner, H., Hedwall, P.R. and Meier, M. (1965). Experentia (Basel), 21, 136–137.
Burnstock, G. (1978). In Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. (eds L. Bolis and R.W. Straub) Raven Press, New York.
Burnstock, G. (1979). In Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides (eds H.P. Baer and G.J. Drummond) Raven Press, New York.
Burnstock, G. (1980). In Handbook of Physiology Sec. 2 The Cardiovascular System, Vol. II, Vascular Smooth Muscle. (eds. D.F. Bohr, A.D. Somlyo, H.W. Sparks and S.R. Geiger). Am. Physiol. Soc. Waverley Press, Baltimore.
Chevillard, C., Saiag, B. and Worcel, M. (1981). Br. J. Pharmacol., 73, 811–817.
Clanachan, A.S., Johns, A, and Paton, D.M. (1977). Neuroscience, 2, 597–602.
Collis, M.G. and Pettinger, S.J. (1982). European J. Pharmacol., 81, 521–529.
De Potter, W.P. (1971). Phil. Trans. R. Soc. (B), 261, 313–317.
Diamond, J. and Janis, R.A. (1978). Nature, 271, 472–473.
Diamond, J. and Janis, R.A. (1979). Br. J. Pharmacol., 68, 275–282.
Douglas, W.W. and Poisner, A.M. (1966). J. Physiol. (Lond), 183, 213–237.
Fredholm, B.B. (1980). TIPS 1, 129–132.
Gross, F. (1977). In Antihypertensive Agents, Handb. Exp. Pharm. XXXIX. (ed. F. Gross) Springer-Verlag, Berlin, Heidelberg, New York.
Gross, F., Druey, J. and Meier, R. (1950). Experentia (Basel), 6, 11–12.
Janis, R.A. and Diamond, J. (1979). J. Pharmacol. Exp. Ther., 211, 480–484.
Khayyal, M., Gross F. and Kreye, V.A.W. (1981). J. Pharmacol. Exp.
Ther., 216, 390–394.
Kirpekar, S.M. and Lewis, J.J. (1957). J. Pharm. Pharmacol., 9, 877–887.
Kirpekar, S.M. and Lewis, J.J. (1958). J. Pharm. Pharmacol., 10, 255–259.
Koch-Weser, J. (1976). New Eng. J. Med., 295, 320–323.
Lagercrantz, J. (1976). Neuroscience, 1, 81–92.
Lipe, S. and Moulds, R.F.W. (1981). J. Pharmacol. Exp. Ther., 217, 204–208.
Londos, C. and Wolff, J. (1977). Proc. Natl. Acad. Sci. U.S.A., 74, 5482–5486.
Marks, P.A., Reynell, P.C. and Bradley, S.E. (1955). Amer. J. Phy-siol., 183, 144–148.
McLean, A.J., Du Souich, P., Barron, K.W. and Briggs, A.H. (1978). J. Pharmacol. Exp. Ther., 207, 40–48.
Moyer, J.H., Handley, C.A. and Huggins, R.A. (1951). J. Pharmacol. Exp. Ther., 103, 368–376.
Page, I.H. (1951). J. Amer. Med. Ass., 147, 1311–1318.
Schroeder, H.A. (1951). J. Clin. Invest., 30, 672–673.
Shepherd, A.M.M., Haegele, K.D., Ludden, T.M., Talseth, T., Clementi, W.A. and Mc Nay, J.L. (1979). Clin. Res., 27, 318.
Smith, A.D. (1972). Pharmacol. Rev., 24, 435–456.
Su, C. (1975). J. Pharmacol. Exp. Ther., 195, 159–166.
Su, C. (1978). J. Pharmacol. Exp. Ther., 204, 351–361.
Van Calker, D., Muller, M. and Hamprecht, B. (1979). J. Neurochem., 33, 999–1005.
Vanhoutte, P.M. (1978). In Microcirculation, Vo1.II, (eds, G. Kaley and B.M. Alturay), University Park Press, Baltimore.
Weiss, G.B., Hatano, K. and Stull, J.T. (1981). Blood Vessels, 18, 230.
Worcel, M. (1978). J. Pharmacol. Exp. Ther., 207, 320–330.
Worcel, M., Saiag, B. and Chevillard, C. (1980). TIPS, 1, 136–138.
Zacest, R. and Koch-Weser, J. (1972). Clin. Pharmacol. Ther., 13, 420–425.
Editor information
Editors and Affiliations
Copyright information
© 1985 The Contributors
About this chapter
Cite this chapter
Brown, N.L., Chevillard, C., Worcel, M. (1985). Purines and Hypertension: Interaction with Hydralazine. In: Stone, T.W. (eds) Purines. Satellite Symposia of the IUPHAR 9th International Congress of Pharmacology. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-07564-5_16
Download citation
DOI: https://doi.org/10.1007/978-1-349-07564-5_16
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-07566-9
Online ISBN: 978-1-349-07564-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)